Evidence map›Paper›PMID 39042352›Full record

ArticleInternational journal of clinical pharmacy2024

Correlates of stocking naloxone: a cross-sectional survey of community pharmacists.

Rose Laing, Ting Xia, Elizabeth Grist, Jana Dostal, Suzanne Nielsen, Louisa Picco

Abstract read
In one paragraph

Article in International journal of clinical pharmacy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Responding to reports of nitazene toxicity in Australia.The Medical journal of Australia · 2025
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Rose LaingMonash Addiction Research Centre, Eastern Health Clinical School, Peninsula Campus, Monash University, 47-49 Moorooduc Hwy, VIC 3199, Frankston, Melbourne, Australia. rose.laing@monash.edu.ORCID https://orcid.org/0009-0001-0094-1332
Ting XiaMonash Addiction Research Centre, Eastern Health Clinical School, Peninsula Campus, Monash University, 47-49 Moorooduc Hwy, VIC 3199, Frankston, Melbourne, Australia.ORCID http://orcid.org/0000-0001-5033-6248
Elizabeth GristMonash Addiction Research Centre, Eastern Health Clinical School, Peninsula Campus, Monash University, 47-49 Moorooduc Hwy, VIC 3199, Frankston, Melbourne, Australia.
Jana DostalMonash Addiction Research Centre, Eastern Health Clinical School, Peninsula Campus, Monash University, 47-49 Moorooduc Hwy, VIC 3199, Frankston, Melbourne, Australia.
Suzanne NielsenMonash Addiction Research Centre, Eastern Health Clinical School, Peninsula Campus, Monash University, 47-49 Moorooduc Hwy, VIC 3199, Frankston, Melbourne, Australia.ORCID http://orcid.org/0000-0001-5341-1055
Louisa PiccoMonash Addiction Research Centre, Eastern Health Clinical School, Peninsula Campus, Monash University, 47-49 Moorooduc Hwy, VIC 3199, Frankston, Melbourne, Australia.ORCID http://orcid.org/0000-0001-7593-3209

Funding

National Health and Medical Research Council 2016909National Health and Medical Research Council 2025894
6 · The paper itself

Abstract

backgroundProvision of take-home naloxone (THN) and overdose education reduces opioid-related mortality. In Australia, from July 2022, all Australian community pharmacies were eligible to supply naloxone for free through the national THN Program.

aimThis study aimed to identify naloxone stocking rates and correlates of stocking naloxone across Australian pharmacies.

methodData were collected from a representative sample of Australian pharmacists in Victoria, New South Wales, Queensland and Western Australia via an online survey. Data collected included pharmacy and pharmacist characteristics and services offered within the pharmacy, including needle and syringe programs, opioid agonist treatment (OAT) and stocking naloxone. Binary probit regression analysis was used to identify correlates of stocking naloxone after controlling for key covariates.

resultsData from 530 pharmacists were analysed. In total, 321 pharmacies (60.6%) reported stocking naloxone. Chain pharmacies and pharmacies that provided OAT had a greater probability of stocking naloxone (B = 0.307, 95%CI: [0.057, 0.556], and B = 0.543, 95%CI: [0.308, 0.777] respectively). Most (61.7%) pharmacists felt comfortable discussing overdose prevention with patients who use prescription opioids, and this comfort was associated with a higher probability of stocking naloxone (B = 0.392, 95%CI: 0.128, 0.655). Comfort discussing overdose prevention with people who use illicit opioids was lower (49.4%) and was not associated with stocking naloxone.

conclusionThere is scope to increase stocking of naloxone and comfort with overdose prevention, particularly through addressing comfort working with higher risk groups such as people who use illicit opioids.

Indexed as

Community Pharmacy ServicesDrug OverdoseNaloxoneNarcotic AntagonistsPharmacistsAdultAustraliaCross-Sectional StudiesFemaleHumansMaleMiddle AgedSurveys and QuestionnairesNaloxoneNarcotic AntagonistsAustraliaCommunity pharmacyHarm reductionNaloxoneOpioidsPharmacist

Identifiers

PMID39042352
PMCPMC11576638

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.